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Abstract The area of pharmaceutical research is broadened with the 
invention of new pharmaceutical drug delivery system. The traditional drug 
deliveries systems have not the way to treat or cure special disease or as well as 
the common disease with less side effects and maximized efficacy. ODDS have 
various advantages and disadvantages but their disadvantages are overcome by 
the CDDS. CDDS although they overcome the disadvantages of ODDS but 
do not handle the special pharmacological disease requirements. To overcome 
this PDDS is established to overcome the disadvantages of CDDS. PDDS has 
gained importance in the drug delivery system because of improved patient 
compliance, therapeutic efficacy and having fewer side effects. PDDS uses 
lag time for delivery of drug in body. Various systems are there in PDDS to 
overcome the patient’s special chronopharmacological needs.
1. INTRODUCTION
Oral route is most convenient, patient friendly route of drug administration 
and does not require advanced technical knowledge and skills to deliver the 
drug as in intravenous and intramuscular routes. Another advantage of oral 
route is that there is no need of special device to deliver the drug to patient. 
Most researches are done on Oral drug delivery system (ODDS) as it is less 
time consuming, cheaper, and requires low cost for production as there is no 
sophisticated  production operations involved like sterilization etc. Traditional 
oral drug delivery system achieves drug-plasma concentration peaks and 
follows bell shaped graph as first order drug release pattern. The disadvantages 
of traditional oral drug delivery system are overcome by controlled release 






uncoated ODDS as they offer less fluctuation in drug plasma peak, low dose 
requirement, decrease in frequency of drug administration, less side effects 
because of low dose, and concentration of drug lies in therapeutic window, 
improved patient compliances etc. But there are disadvantages with CDDS 
like dose dumping. To overcome this, special requirements are required which 
give rise to new area of research called Pulsatile drug delivery system (PDDS). 
There are some special conditions which require release of drug after a certain 
period of time called lag time to achieve optimum concentration at required 
time and required site. The release phase of drug is retarded in its initial phase 
but release is required after lag time. This type of drug formulations which have 
lag time and release drug after lag time are come under Pulsatile drug delivery 
system(PDDS). Recent studies showed that diseases which are circadian 
rhythm follower are overcome if medication timing is proper or optimized. 
The explanations of biological clock are given by three rhythms in body which 
are set up by the natural biological clock of the body operated by SCN present 
in hypothalamus gland. The three types of rhythms are:
1. Circadian rhythm: Circa means ‘about’ and dian means ‘day’.
2. Ultradian rhythm: Oscillations of shorter duration are come under 
Ultradian rhythm generally oscillation or cycle of more than one in 24hrs.
3. Infradian rhythm: Oscillation longer than 24hrs generally less than one 
oscillation or cycle in day.
These circadian rhythms are the conceptual milestone in development and 
formulation of PDDS. Circadian rhythms are self sustaining, endogenous 
oscillations (1). These have periodicities of 24hrs or a day.
Figure 1: Circadian Rhythm Cycle and Disease Associated.
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2. REASONS TO ADOPT PDDS
1. First pass metabolism: The beta blockers undergo extensive first pass 
metabolism in intestine and liver. PDDS gives sigmoidal release which 
releases the drug rapidly and saturates the enzymes thus retarding rate 
of first pass metabolism as seen in PDDS. This results in increased oral 
bioavailability of beta blockers.
2. Special chronopharmacological needs: Circadian rhythms are seen at 
specific time in 24 hrs for particular disease like asthma and angina. This 
potentiates to the development & role of PDDS formulations which work 
according to circadian rhythms.
3. Local therapeutic needs: Sometimes local therapeutic effect of drug 
is desired as seen in inflammatory bowel disease, peptic ulcer and other 
targeting like colon and ileum which require release of drug after lag time 
along with site specific delivery.
4. Stability problems: Drugs causes high git irritation and drugs which are 
unstable in gastric fluid are formulated by PDDS, having lag time more 
than the gastric residence time.
5. Absorption windows: Different drugs having different absorption site at 
git tract. The targeting to the specific absorption window is achieved by 
PDDS by varying the lag time of formulation up to the desired site of 
absorptions.







6. For potent drugs: Drugs having narrow therapeutic window like digoxin 
and drugs having fluctuating peak plasma concentration like theophyline 
can be formulated in PDDS to overcome fluctuating peak plasma 
concentration of drug.
7. Inter and Intra subject variability: Inter and intra subject variability is 
seen for various drugs like theophyline etc which is overcome by PDDS.
Table 1: Circadian Rhythm and Menifestations of Diseases.
Disease and Syndrome Complications seen by patients
Asthma Complications arises during 2am-5am early morning.
Angina Pectoris Severe pain during morning and exercise.
Hormone secretions During night in relaxing phase eg: testosterone secre-tions
Myocardial infaraction During early morning.
Cardiac death During awakening from sleep.
Peptic ulcers Late evening and early morning symptoms are seen
Stroke Morning time.
Allergic rhinitis Worse symptoms are seen in morning.
Osteoarthritis In middle of the day.
METHODOLOGIES USED IN PDDS
1) Time controlled PDDS
 a) Single Unit Systems
  i) Capsular systems
  ii) Tablet systems
  iii) Port systems
  iv) Osmotic pressure systems
  v) Based on solubility modifications.
  vi) Reservoir system
 b) Multi Particulate Systems.
  i) Rupturable coating systems
  ii) Time controlled explosion system
  iii) Sigmoidal release systems
  iv) Modified permeation systems
  v) Floating delivery based systems
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2) Stimuli Induced PDDS
 a) Internal stimuli induced
  i) Temperature induced
  ii) pH based
  iii) Glucose sensitive system
  iv) Inflammation based
  v) Intelligent gel based
  vi) Enzyme based
 b) External stimuli based
  i) Electro responsive
  ii) Magnetically induced
  iii) Ultra sound induced
  iv) Light induced
3) PDDS for hormones and vaccines
4) Recent advanced patented PDDS technologies
 a) Spheroidal oral drug absorption system
 b) Intestinal protective drug absorption system
 c) Chronotherapeutic oral drug absorption system
 d) PULSYSTM technology
 e) EURENDS pulsatile and chrono release systems
 f) GEOCLOCK technologies
1) TIME CONTROLLED PDDS: A) SINGLE UNIT SYSTEM
  i) CAPSULAR SYSTEM
     Various capsular systems have been developed now a days. The 
fundamental method of capsular system consists of an insoluble 
capsule body housing a drug and a plug in it. The body is closed 
at the open end with a swell able hydrogel plug. Upon contact with 
dissolution medium or GIT fluid the plug swells pushing itself out 
of the capsule body after a lag time. The lag time is controlled by 
manipulating the dimension and position of plug. Higher the thickness 
and greater the length the more will be the lag time. Another factor 
which decides lag time is the position of plug, the deeper the plug 
inserted, the more will be the lag time because when plug swells 






drugs have different requirements like incorporating API along with 
effervescent agents and disintegrants. The plug consists of permeable 
and swellable polymers (polymethacrylates), erodible compressed 
polymers (polyvinyl alcohols, hydroxyl propyl methyl cellulose), 
congealed melted polymers (glycerides) and enzymatically controlled 
polymers (pectin).
 ii) TABLET SYSTEM
    In this type of drug delivery system, the lag time is controlled by the 
coating of erodible polymer on the core tablet containing the drug. 
The thickness of polymer used and type of polymer used decides 
the lag time of the tablet. They may be enteric coated and followed 
by pulse release of the drug. The choice of enteric coated polymer 
depends upon the pH of the delivery site of intestine (11). Examples 
of polymers used are Cellulose acetate phthalate (CAP), methyl 
cellulose phthalate etc (9).
 iii) PORT SYSTEMS
     Port system Consists of gelatin capsule coated with a semi permeable 
membrane, for example like cellulose acetate having insoluble plug 
(lipidic) along with osmotically active agent with drug formulation. 
When it comes in contact with the GIT fluid the fluid penetrates the 
semi permeable membrane because of osmotic pressure exerted by 
osmotically active agents. This forms a port to enter the liquid and 
drug is dissolved by this penetrated liquid. The liquid drugs can also be 
formulated by this method. The liquid drug is absorbed by the bigger 
particles which are highly porous. The capsule body is insoluble in 
GIT fluids but the cap of capsule is soluble in GIT fluid. The insoluble 
plug is fitted on the upper part of body of the capsule. The osmotic 
Figure 3: Tablet system showing enteric system with lag time.
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agents are incorporated in the capsule (13). The capsule body or plug 
one of either has made up of elastic semi permeable membrane. This 
membrane helps the fluid for movement of liquid inside to outside 
and vice-versa. The osmotic active agents’ creates higher osmotical 
pressure inside capsule which causes fluid to penetrate the semi-
permeable membrane. The dissolved drug move outside from elastic 
plug or membrane. It may be noted that not whole drug dissolves at 
one time, only the fraction of drug dissolves out.
 iv) OSMOTIC PRESSURE BASED SYSTEM
     This system is made up of immediate release and pulsatile released 
part. The immediate released part may contain powdered drug, tablet, 
capsule and any combination of novel drug particles like liposomes, 
niosomes etc. This immediate release part is subjected to achieve the 
immediate therapeutic concentration of drug in plasma. The pulsatile 
release part have to achieve ‘pulse’ type release after immediate 
release to achieve and maintain therapeutic concentration thereafter 
immediate part. This pulsatile release part is osmotically charged 
or have osmotically programmed pump. Osmotic delivery is given 
by single osmotic pump or by series of stops separated by movable 
partitions. These stops obstruct the movement of partition but are 
overcome by liquid as osmotic pressure is there. Number of stops and 
longitudinal placements of stops in capsule tells the frequency and 
number of drug released as pulses.
 v) BASED ON SOLUBILITY MODIFICATION
          Solubility modification of the drug carrier like capsule housing 
is modified by various methods to give pulsatile release of the drug 
after lag time. The solubility of the capsule shell is modified by 
formalin. The capsule shells treated with formalin have reported time 






dependent insolubility of the 24hrs. The capsule shells placed on wire 
mesh which is placed on some height on desiccators. In the desiccator 
base formaldehyde solution is placed with small amount of potassium 
permanganate & then closed. The formalin vaporises evolved and 
get adsorbed on gelatin capsules surface and varies their solubility. 
In practical measure only 10 capsules are shrinked in group of 100 
capsules. The drug incorporated may be tablet, pellets, niosomes, 
liposomes etc.
 vi) RESERVOIR SYSTEMS
     Reservoir system consists of the drug reservoir or ‘drug depot’ in 
capsule body or polymer layers on tablet or any other pulsatile 
system. Drug is released from this depot which may or may not 
be the control released or pulsatile released. This type of reservoir 
system is constructed of three parts first is core tab containing ‘api’, 
second one is erodible outer layer and last is external outer layer.
A)  MULTIPARTICULATE SYSTEM
 i) RUPTURABLE COATING SYSTEM
   This system is based on the expansion of core which then rupture the 
coating to allow rapid release of the drug. This system is mostly used 
in floating type of pulsatile drug delivery systems. The fundamental 
formulation of rupturable coating system is made up of drug with 
effervescent material and a polymeric coating. HPMC is used as 
polymeric coating (7). Drug with effervescent material like sodium 
bicarbonate is used and gas trapped in the membrane which is made 
Figure 5: Capsule body having osmotically based system 3.
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up of eudragit RL because Eudragit RL degrades at pH 5-6, so it  will 
not degrade in stomach and the gas evolved lowers the density and 
floats in stomach fluids (6).
 ii)  TIME CONTROLLED EXPLOSION SYSTEM
     These system consists of osmotically active layer, core pellet or core 
tablet and third one outermost layer is enteric coated layer. The core 
tablet is made up of ‘api’ and other excipients. The swelling layer 
is made up of osmotically active agent. The swelling layer consists 
of semi permeable membrane because of expulsion of membrane to 
degrade enteric coating and gives desired lag time. The concentration 
of enteric coated layer, osmotically active agents, and semi permeable 
membrane affects the lag time (14).
 iii)  SIGMOIDAL RELEASE SYSTEM
      Sigmoidal release system is made up of core drug i.e. pellets or tablet 
compressed along with succinic acid. The drug and succinic acid 
pellets are coated with the ammonium methacrylate polymers type-b 
which is used as semi permeable membrane. When water comes in 
contact with the system drug succinic acid gets dissolved (5). The 
acid increases the permeability of the semi permeable membrane. 
Beside succinic acid other acids used are tartaric acid, acetic acid, 
glutaric acid, malic acid and citric acid (3).
 iv)  MODIFIED PERMEATION SYSTEM
      The pulsatile drug delivery system is made by change in membrane 
permeability, has taken much interest nowadays. The change in 
membrane permeability acts similarly as the typical ion exchange 






resins. An acrylic polymer with quartnery ammonium groups has 
been influenced by various ions in medium. Eudragit RS contains 
positively charged quartnery ammonium group in polymer chain 
(13). This ammonium group has interaction with the water there by 
changing the permeability. This modified permeation leads the water 
to penetrate and dissolves the drug.
 v)   FLOATING TYPE DRUG DELIVERY
     (1)  Floating type drug delivery along with pulsatile drug delivery 
system serving the both site specific and time specific drug 
delivery. Floating type drug deliveries have increased GIT 
resident time of drug and give site specific targeting while 
PDDS gives lag time like feature for time specific drug 
delivery1). This consists of buoyancy layer, coating layer 
which is insoluble and core material. Buoyancy layer may 
consist of effervescent agents, low density material, gelling 
system which make raft like consistency on GIT fluid. Coating 
layer depends upon the pH of the targeted site i.e. intestine and 
colon hence the polymer is decided.
2) STIMULI INDUCED PDDS
  a) INTERNAL STIMULI INDUCED
   i) TEMPERATURE BASED 
            Temperature is mainly used as stimulus to release the drug 
in pulsatile manner. Temperature based polymers are used 
to develop temperature based PDDS.Several hydrogel based 
systems are used to formulate PDDS. The temperature sensitive 
polymers either swell or deswell during release phase in PDDS. 
Basically acryl amides are used in temperature sensitive PDDS. 
There are two types of temperature based PDDS:
•	 Thermo responsive hydrogel system: This type employs 
hydrogels in which there is volume shift i.e. swell or deswell. 
These hydrogel shrink at temperature, known as LCST (lower 
critical solution temperature) of linear polymer. This increases 
the miscibility of hydrogel as dispersion but when the temperature 
rises up to the HCST (higher critical solution temperature), this 
result in swelling of hydrogel and release of the drug.
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•	 Thermo responsive polymeric micelle system: The thermo 
responsive micelle system is achieved by the tightly bound 
drug in micelles and release of drug in controlled manner 
which depends upon the temperature stimulus. The polymers 
used are poly(N-isopropyl acryl amide) i.e. [PNIPAM]-grafted 
polyphosphazene[PNIPAM-g-PPP] formed by co-substitution 
of chlorine atoms on polymeric backbones with amino 
terminated Nipam oligomers and ethyl glycinate.
  ii) pH BASED
           pH based PDDS is based on the pH sensitive polymers that 
are polyelectrolytes in nature. These polyelectrolytes have acidic 
or basic group that either accept or donate protons when pH is 
changed. They dissolve, swell and shrink when subjected to 
change of pH as a stimulus. Various polymers which are used in 
pH based PDDS are cellulose acetate phthalate, sodium carboxy 
methyl cellulose and polyacrylates. These polymers can also be 
used as coating to tablet, pellets, capsules, liposomes, niosomes 
to produce pH sensitive PDDS (13). In this case immediate 
release drug may or may not be loaded before pulsatile release of 
drug.
  iii) GLUCOSE SENSTIVE SYSTEM
            These types of systems are specially used in the case of Diabetes 
mellitus, when there is rise in the glucose concentration in the 
patient’s blood and need insulin at that time. This is a system 
which respond to blood glucose i.e. pH sensitive hydrogel 
containing glucose oxidase immobilized enzyme in it. When 
glucose concentration in blood increases glucose oxidase convert 
glucose to gluconic acid decreases the pH toward acidic. This 
acidic pH cause swelling of polymer resulting in insulin release 
from hydrogel. Examples of polymer used are chitosan, polyol, 
N, N-dimethyl aminoethyl methacrylate (15).
  iv) INFLAMMATION BASED
            Physical or chemical stress and any injury results in release 
of inflammation mediators that produce hydroxyl radicals. The 
design of this type of drug delivery is based on the polymers 
which respond to the hydroxyl radicals and degraded in limited 






radicals or enzyme known as hyaluronidase. Degradation of 
hyaluronic acid via hyaluronidase is very low and normal state 
of health. But degradation by hydroxyl radical is very rapid when 
hyaluronic acid is injected at inflamed sites. Then it is possible 
to treat patients with disease like rheumatid arthritis with anti 
inflammatory drug and hyaluronic acid.
  v) INTELLIGENT GEL BASED
           There are several types of gels which respond to antigen antibody 
complex. There are bioactive materials present in the body like 
antibodies which respond to novel gels to alter their swelling 
and deswelling properties. These have focus on antigen antibody 
complex as there are specific antibodies for the specific disease. 
The swelling and de-swelling changes permeation to gels. This 
volume shift phenomenon releases the drug from gels.
  vi) ENZYME BASED SYSTEM
            Liposomes in combination with micro capsule of alginate beads 
is used as enzyme based system. Drug is loaded in liposomes by 
suitable methods which were loaded in microcapsules. The loaded 
liposomes are first coated with phospholipase A2 enzyme for PDDS. 
Phospholipase A2 removes the acyl group from phospholipids. 
These liposomes release drug molecules from them.
 b) EXTERNAL STIMULI INDUCED
   i) ELECTRORESPONSIVE
           The electro responsive delivery systems uses polymers which 
have very high ionisable group in parent chains because when 
electric stimulus there they get ionized and release drug. 
Thus ionizing polymers act both as electro responsive and pH 
responsive polymer. Examples of polymers include agarose, 
xanthan gum, chitosan, carbomer, calcium alginate etc.
  ii) MAGNETICALLY INDUCED
           The use of external magnetic field as stimulus in magnetically 
induced delivery has increased because of very less side effects 
on human body. Oscillating magnetic field leads to the controlled 
release of the drug. Magnetic carriers receive magnetic 
response from incorporated material such as magnetite, iron, 
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nickel, cobalt etc. The behaviors of intelligent ferrogels were 
studied by Tingyu liu. The ferrogels called intelligent magnetic 





magnetic particles through freeze thaw 





 & accumulates drug around ferrogel. When 
magnetic field is released rapidly. The slow release of drug 
can be adjusted by switching ‘off’ and ‘on’ the magnetic 





 under magnetic field. Another simple approach is by 
incorporating magnetic particle in capsule or tablet thus slowing 
down their speed by external magnetic field in GIT tract.
  iii) ULTRASOUND INDUCED
            Ultrasound waves are used in transdermal drug delivery as it 
increases the permeation of skin by physically reversible change 
in pore size of skin walls. But recently ultrasound waves are used 
in PDDS. Ultrasonic waves have been divided into two broad 
categories based on their effect produced: First is thermal effect 
producing in which fluids absorb energy and drug is released 
from temperature sensitive polymers (12). Second is non thermal 
ultrasonic waves in which oscillating bubbles and disturbances 
are used to fill cavities.
  iv) LIGHT INDUCED
           The light sensitive polymers are made with light sensitive 
hydrogels & used in ophthalmic deliveries. Light is used as the 
stimulus to release the drug. When light responsive hydrogel 
absorbs light  there is rise in temperature and hydrogel collapse 
at lowest critical solution temperature and drug is released from 
matrices (12). The light sensitive polymers act as temperature 
sensitive polymers to release their drug.
3) PDDS FOR HORMONES AND VACCINES
Vaccines require initial dose of antigen with repeated booster doses to produce 
immunity in body. The dose regimen of the vaccine is antigen dependent. 
PDDS can do this job in a single administration by initially giving dose with 
time controlled booster doses. Vizcarra et al administered GnRh in nutritionally 
anoestrous cows in pulses of 2mg up to 5 min every hour for 13 days, after 13 






4) RECENT ADVANCES IN PDDS:
 a)  SPHEROIDAL ORAL DRUG ABSORPTION SYSTEM 
(SODAS)
    Production of controlled release beads give rise to customized dosage 
form that responds directly to individual drug candidate needs. 
Controlled release beads can be formulated with immediate release 
drug to achieve peak plasma concentration in body.
 b)  INTESTINAL PROTECTIVE DRUG ABSORPTION SYSTEM 
(IPDAS)
    Use of high density multiparticulate tablet technology is used for 
GIT irritant compounds. IPDAS have number of high density 
controlled release beads which are compressed into tablet form. 
When tablet is ingested it breaks and releases the beads. Beads go to 
intestine and release of drug from beads is given by diffusion through 
polymeric membrane. Example is Naprelean® having naproxen 
sodium.
 c)  CHRONOTHERAPEUTIC ORAL DRUG ABSORPTION 
SYSTEM (CODAS)
         CODAS is a time controlled PDDS and causes drug release after a long 
lag time when administered to the patient. The lag time is generally 
4-5 hrs after administration of drug. A controlled release polymer is 
coated on the beads having combination of water soluble and insoluble 
polymer. Water soluble polymer slowly dissolves and drug diffuses 
through pores from coating, while same time water insoluble polymer 
continues to act as barrier maintaining controlled release of the drug. 
 d) GEOCLOCK TECHNOLOGY
   Geoclock® tablets have been used as an API inside an outer tablet 
layer having mixture of hydrophobic wax with brittle material in order 
to obtain a pH dependent lag time. Dry coating approach is designed 
to allow the time release of both slow and fast release components.
 e) PULSYS™ TECHNOLOGY
   This technology gives once daily pulse release of drug which is 
actually made up of compressed tablets that contains pellets which 
are previously designed to release drug at different sites of GIT tract 
in pulsatile manner. The transit properties of pellets enhance overall 
absorption time and offers improved bioavailability.
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 f) EURAND’S PULSATIL AND CHRONO RELEASE SYSTEM
   This system is capable of providing one or more rapid release pulses at 
predetermined time lags. The drug pulse is given out from formulation 
at predetermined lag period. This increases efficiency and minimizes 
the side effects. Example includes propanlol hydrochloride with a 4hr 
delay in release after oral administration. When administered at bed 
time the maximum plasma level concentration of drug occur in early 
morning when patient have risk of cardiac problems.
ADVANTAGES OF PDDS
•	 Extended day and night presence of optimum drug concentration in body.
•	 Reduced side effects.
•	 Reduced dose frequency.
•	 Reduction of the drug used in dosage form.
•	 Improved patient compliance due to less dosing frequency.
•	 Drug targeting to colon and distinct place in git.
•	 Administration of gastric unstable drug is easier.
•	 Beneficial for the diseases which follows circadian rhythms.
 DISADVANTAGES OF PDDS
•	 Low drug loading formulation.
•	 Multiple steps involved leads to variation in quality of dosage form.
•	 Incomplete release of the drug.






























•	 Immediate withdrawal of the drug is not possible.
•	 Dose calculation for child and elder patient is difficult.
•	 In vivo variability may be seen in special cases.
CONCLUSION
There are various ways to formulate PDDS, but the design and choice of the 
effective method in developing of PDDS is dependent upon patients condition, 
drugs inherent properties, target site, lag time needed etc. The upper description 
of methods is based on methods established and new methods which are under 
development. Thus in real PDDS can take over traditional oral as well as the 
controlled and sustained release formulation for better efficacy. But this era is 
developing era of PDDS and the diseases which are controlled by circadian 
rhythm can be effectively managed by PDDS in future. Beside this various 
marketed formulation of PDDS are present in market and serving for effective 
disease management in recent years.
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